Navigation Links
Drugs targeting chromosomal instability may fight a particular breast cancer subtype
Date:2/6/2012

PHILADELPHIA -- Another layer in breast cancer genetics has been peeled back.

A team of researchers at Jefferson's Kimmel Cancer Center (KCC) led by Richard G. Pestell, M.D., PhD., FACP, Director of the KCC and Chair of the Department of Cancer Biology, have shown in a study published online Feb. 6 in the Journal of Clinical Investigation that the oncogene cyclin D1 may promote a genetic breakdown known as chromosomal instability (CIN). CIN is a known, yet poorly understood culprit in tumor progression.

The researchers used various in vitro and in vivo model systems to show that elevated levels of cyclin D1 promotes CIN and correlate with CIN in the luminal B breast cancer subtype. Cyclin D1 protein is elevated in breast, prostate, lung and gastrointestinal malignancies.

The findings suggest that shifting towards drugs targeting CIN may improve outcomes for patients diagnosed with luminal B subtype. Luminal B breast cancer has high proliferation rates and is considered a high grade malignancy.

Estrogen or progesterone receptor positive and HER2 positive cancers indicate luminal B, and about 10 percent of patients are diagnosed with it every year, though many do not respond well to treatment. The identification of CIN in luminal B provides a new therapeutic opportunity for these patients.

"Cyclin D1 has a well defined role in cell proliferation through promoting DNA replication," says Dr. Pestell. "My team was the first to discover that cyclin D1 also has alternate functions, which include regulating gene transcription at the level of DNA. We were interested in discovering the function of DNA associated cyclin D1."

To help answer this, the researchers, including lead author Mathew C. Casimiro, Ph.D., of the Department of Cancer Biology at Thomas Jefferson University, first needed to directly access cyclin D1's role in gene regulation.

They applied an analysis known as ChIP sequencing to study the protein's interactions with genes that comprise the entire mouse genome, and found it occupied the regulatory region of genes governing chromosomal stability with high incidence.

They went on to show cyclin D1 promoted aneuploidy and chromosomal rearrangements typically found in cancers.

Faulty chromosomeseither too many or too few, or even ones that are the wrong shape or sizehave been shown to be the crux of many cancers. However, a major question of cancer genetics is the mechanisms of CIN. What causes the breakdown in chromosomal stability?

As cyclin D1 expression is increased in the early phases of tumorigenesis, cyclin D1 may be an important inducer of CIN in tumors.

To analyze the association between CIN and cyclin D1 expression in the context of breast cancer, the team aligned an expression of a 70-gene set with the highest CIN score against over 2,000 breast cancer samples. They stratified the samples based on previously described subtypes and aligned them with cyclin D1 expression profiled across the dataset.

A significant correlation among CIN, cyclin D1 and the luminal B subtype was identified, and it was apparent that the relationship between these levels was subtype specific.

"Interestingly, previous studies have presented contradictory results," Dr. Pestell says. "Many studies have suggested a positive correlation between cyclin D1 expression and outcomes, while others have shown reduced survival. Here, we've dug deep, using a genome-wide analysis, and found that overexpression of the protein appears to be directly associated with the genes involved in CIN and this correlates with the luminal B subtype."

Drugs targeting chromosomal instability for cancer therapy have been explored, but a sub-stratification rationale for the luminal B subtype has not been established. The research presented in this study suggests such a target is worthy of further investigation.

"There is a big drive towards using targeting therapies for stratified breast cancers," says Dr. Casimiro. "What we are thinking is that there are a growing number of drugs that target aneuploidy, like AICAR and 17-AAG, that may be used as an adjuvant therapy in patients with luminal B breast cancer."


'/>"/>
Contact: Steve Graff
stephen.graff@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert  

Related medicine news :

1. Websites advertising cholesterol-lowering drugs of poor quality
2. Many children with liver transplants from parents can safely stop using anti-rejection drugs
3. Heartburn Drugs May Raise Fracture Risk in Older Women
4. Experimental Drugs Do Battle Against Advanced Prostate Cancer
5. NIH launches trials to evaluate CPR and drugs after sudden cardiac arrest
6. UC Davis researchers refine nanoparticles for more accurate delivery of cancer drugs
7. Researchers study how chemicals in drugs and around us impact stem cells
8. Counterfeit and substandard anti-malaria drugs threaten crisis in Africa, experts warn
9. Combining 2 anti-HER2 drugs may provide better preoperative breast cancer treatment
10. 1 in 10 Canadians cannot afford prescription drugs: UBC study
11. Certain Diabetes Drugs Might Aid Weight Loss
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drugs targeting chromosomal instability may fight a particular breast cancer subtype
(Date:2/10/2016)... ... February 10, 2016 , ... MetLoop CEO ... new 2.0 version at the International Roofing Expo in Orlando, Florida on February ... world's most advanced weather technology in the hands of consumers, roofing contractors, manufacturers ...
(Date:2/10/2016)... ... 2016 , ... The Wickman Agency in Garland, TX has ... community. Pledging to select a new beneficiary every 60 days, the agency will ... is to bring community awareness to important local causes by forming campaigns which ...
(Date:2/10/2016)... Tucson, AZ (PRWEB) , ... February 10, 2016 , ... ... prompted the Aging Life Care Association™ (ALCA) to conduct a survey that takes a ... aging experts released today illustrates the prevalence and causes of TBI among the aging ...
(Date:2/10/2016)... ... 10, 2016 , ... Armune BioScience signed a definitive agreement with ... service centers across the country. Launched in April of 2015, Apifiny is the only ... cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Club ... awarded the prestigious Distinguished Emerald Club of the World award, as determined by ... one of the most respected trade publications serving private clubs. , “We’d like ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , February 10, 2016 ... "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market ... Technologies, Participants, and Environment" research report indicates that ... over $149 billion by 2020 growing at a ... of companion diagnostics and targeted therapeutics and is ...
(Date:2/9/2016)... CITY, Calif. , Feb. 9, 2016 /PRNewswire/ - ... device company that is providing innovative evidence-based solutions for ... will release financial results for the fourth quarter and ... February 29, 2016. Company management will host a conference ... Eastern Time) on Monday, February 29, 2016. ...
(Date:2/9/2016)... BILLERICA, Mass. , Feb. 9, 2016  Insulet Corporation ... in tubeless insulin pump technology with its OmniPod ... David A. Lemoine has been appointed to Insulet,s ... comprised of nine directors, eight of whom are independent. ... over 40 years of audit and finance experience and a ...
Breaking Medicine Technology: